Potrero Medical’s Accuryn AKI Predict Algorithm Earns Breakthrough Status

Potrero Medical has earned U.S. Food and Drug Administration (FDA) breakthrough status for its AKI (acute kidney injury) Predict machine learning algorithm, which predicts AKI associated with intra-abdominal hypertension (IAH) for patients in post-surgical intensive care.
 

“We celebrate the breakthrough designation, and we are excited about what this will mean for patients, providers and health systems in the future,” Joe Urban, Potrero CEO told the press. “Continuous urine output and intra-abdominal pressure are new patient parameters that, until Accuryn, have not been available to leverage as critical data streams. Combining Accuryn technology with a predictive AKI algorithm will enhance the clinical decision support we provide at the bedside.”
 
Potrero aims to transform patient care via precision fluid management and analytics for clinical decision support from precise data from the kidney, using the latest advances in artificial intelligence and sensors.